Clinical Trial Detail

NCT ID NCT03126461
Title SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Texas Southwestern Medical Center
Indications

melanoma

Therapies

Ipilimumab + Nivolumab

Age Groups: senior adult

No variant requirements are available.